ArticleCardiology journal2025
Transcatheter closure of patent ductus arteriosus in infants weighing less than 6 kilograms - a two-center experience. Technical considerations.
Article in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter closure has become the method of choice for treating patent ductus arteriosus (PDA) in a majority of patients. The only approved device for treating infants weighing less than 6 kilograms is the Amplatzer Piccolo Occluder (APO). The aim of this study is to summarize the experience of two centers in performing transcatheter PDA closure in infants weighing less than 6 kilograms.
methodsRetrospective, descriptive, and nonrandomized analysis included all 45 infants weighing less than 6 kg who underwent transcatheter PDA closure between 2013 and 2023 at two tertiary centers, following the introduction of APO. Medical records, procedural outcomes, and one-month follow-up were analyzed. Applied devices were: APO in 37 (of whom 3 were off-label due to PDA size), Amplatzer Duct Occluder I (ADO) in 3, and Amplatzer Vascular Plug II (AVP) in 5 cases.
resultsThe overall success rate was 97.8%. There were 2 major complications (4.4%), including one device protrusion. A residual shunt was noted in one patient 24 hours after the procedure, but none were observed after one month. Off-label devices were implanted in insignificantly larger and longer PDAs. There were no significant differences between the labeled and off-label groups in terms of procedural success, major complications, or residual shunts.
conclusionsAPO is a safe and effective device to treat PDA in infants weighing less than 6 kilograms, however, off-label devices are needed in a considerable number of patients. Proper use of off-label devices yields comparable to APO results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.